299 related articles for article (PubMed ID: 29910669)
1. New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer.
Sánchez-Gundín J; Fernández-Carballido AM; Martínez-Valdivieso L; Barreda-Hernández D; Torres-Suárez AI
Int J Med Sci; 2018; 15(7):659-665. PubMed ID: 29910669
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
Kirstein MM; Lange A; Prenzler A; Manns MP; Kubicka S; Vogel A
Oncologist; 2014 Nov; 19(11):1156-68. PubMed ID: 25326159
[TBL] [Abstract][Full Text] [Related]
4. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
[TBL] [Abstract][Full Text] [Related]
5. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
6. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
8. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
Moreau LC; Rajan R; Thirlwell MP; Alcindor T
Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831
[TBL] [Abstract][Full Text] [Related]
9. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
10. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
[TBL] [Abstract][Full Text] [Related]
11. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
12. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Moosmann N; Heinemann V
Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
[TBL] [Abstract][Full Text] [Related]
15. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
16. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
17. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
18. Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer.
Bekaii-Saab T; Wu C
Crit Rev Oncol Hematol; 2014 Jul; 91(1):9-34. PubMed ID: 24534706
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
20. A review of the evolution of systemic chemotherapy in the management of colorectal cancer.
Gustavsson B; Carlsson G; Machover D; Petrelli N; Roth A; Schmoll HJ; Tveit KM; Gibson F
Clin Colorectal Cancer; 2015 Mar; 14(1):1-10. PubMed ID: 25579803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
